Good to see you still around peaceAKKI.
Very good news for PAB.
One could speculate that if upcoming trials are a success, and SM6 gets breakthrough therapy designation also, the SP could be a lot higher than it is today.
Especially with the weight of Amgen behind it.
Bodes well for monoclonal antibodies in general.
Success with SM6 also validates PAB's manufacture system and technology in general.
Also points to the value potential of its suite of upcoming antibodies.
A bottom in for the SP?
good for pab/sm6, page-9
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.003(50.0%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $75.03K | 20.76M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 22737453 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 19688236 | 9 |
View Market Depth
| Last trade - 11.57am 02/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |